Lisocabtagene Maraleucel Approved for Use in Relapsed/Refractory Large B-Cell Lymphoma

被引：0
|
作者：
Schuyler, Devon
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：175 / 175
页数：1
相关论文
共 50 条
  • [41] Pivotal Safety and Efficacy Results From TRANSCEND NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphomas
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 8 - 10
  • [42] Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma
    Ken Ogasawara
    Michael Dodds
    Timothy Mack
    James Lymp
    Justine Dell’Aringa
    Jeff Smith
    Clinical Pharmacokinetics, 2021, 60 : 1635 - 1635
  • [43] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M. G.
    Zenz, T.
    Rosler, W.
    SWISS MEDICAL WEEKLY, 2020, : 21S - 21S
  • [44] Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma
    Ahmed, Gulrayz
    Furqan, Fateeha
    Nasrollahi, Elham
    Hamadani, Mehdi
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (08) : 705 - 715
  • [45] Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Schuster, Stephen J.
    Bishop, Michael R.
    Tam, Constantine S.
    Waller, Edmund K.
    Borchmann, Peter
    McGuirk, Joseph P.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Andreadis, Charalambos
    Westin, Jason R.
    Fleury, Isabelle
    Bachanova, Veronika
    Foley, S. Ronan
    Ho, P. Joy p
    Mielke, Stephan
    Magenau, John M.
    Holte, Harald
    Pantano, Serafino
    Pacaud, Lida B.
    Awasthi, Rakesh
    Chu, Jufen
    Anak, Ozlem
    Salles, Gilles
    Maziarz, Richard T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01): : 45 - 56
  • [46] Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
    Armand, Philippe
    Rodig, Scott
    Melnichenko, Vladimir
    Thieblemont, Catherine
    Bouabdallah, Kamal
    Tumyan, Gayane
    Ozcan, Muhit
    Portino, Sergio
    Fogliatto, Laura
    Caballero, Maria D.
    Walewski, Jan
    Gulbas, Zafer
    Ribrag, Vincent
    Christian, Beth
    Perini, Guilherme Fleury
    Salles, Gilles
    Svoboda, Jakub
    Zain, Jasmine
    Patel, Sanjay
    Chen, Pei-Hsuan
    Ligon, Azra H.
    Ouyang, Jing
    Neuberg, Donna
    Redd, Robert
    Chatterjee, Arkendu
    Balakumaran, Arun
    Orlowski, Robert
    Shipp, Margaret
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (34) : 3291 - +
  • [47] Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Harris, Leonard Jeff
    Patel, Kruti
    Martin, Michael
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 12
  • [48] Phylogenetic Evolution in Refractory/Relapsed Diffuse Large B-Cell Lymphoma
    Ruminy, Philippe
    Rainville, Vinciane
    Mareschal, Sylvain
    Etancelin, Pascaline
    Joly, Berangere
    Picquenot, Jean-Michel
    Bastard, Christian
    Tilly, Herve
    Jardin, Fabrice
    BLOOD, 2012, 120 (21)
  • [49] Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused"
    Kesireddy, Meghana
    Lunning, Matthew A.
    ONCOLOGY-NEW YORK, 2022, 36 (06): : 360 - 369
  • [50] Novel agents in relapsed/refractory diffuse large B-cell lymphoma
    Varma, Gaurav
    Goldstein, Jordan
    Advani, Ranjana H.
    HEMATOLOGICAL ONCOLOGY, 2023, 41 : 92 - 106
12345